A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg; CLARITY study group

doi:10.1056/NEJMoa0902533

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven J Greenberg, CLARITY study group

Department of Clinical Medicine

Research output: Contribution to journal › Journal article › Research › peer-review

905 Citations (Scopus)

Abstract

Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

Original language	English
Journal	New England Journal of Medicine
Volume	362
Issue number	5
Pages (from-to)	416-26
Number of pages	11
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMoa0902533
Publication status	Published - 4 Feb 2010

Access to Document

10.1056/NEJMoa0902533

Library access?

Check availability at the Royal Danish Library

Cite this

@article{8ab122da9d49401fa3967ead6ad03d08,

title = "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis",

abstract = "Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.",

author = "Gavin Giovannoni and Giancarlo Comi and Stuart Cook and Kottil Rammohan and Peter Rieckmann and {Soelberg S{\o}rensen}, Per and Patrick Vermersch and Peter Chang and Anthony Hamlett and Bruno Musch and Greenberg, {Steven J} and S{\o}rensen, {Per Soelberg}",

note = "2010 Massachusetts Medical Society",

year = "2010",

month = feb,

day = "4",

doi = "10.1056/NEJMoa0902533",

language = "English",

volume = "362",

pages = "416--26",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "5",

}

TY - JOUR

T1 - A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

AU - Giovannoni, Gavin

AU - Comi, Giancarlo

AU - Cook, Stuart

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Soelberg Sørensen, Per

AU - Vermersch, Patrick

AU - Chang, Peter

AU - Hamlett, Anthony

AU - Musch, Bruno

AU - Greenberg, Steven J

AU - CLARITY study group

N1 - 2010 Massachusetts Medical Society

PY - 2010/2/4

Y1 - 2010/2/4

N2 - Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

AB - Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

U2 - 10.1056/NEJMoa0902533

DO - 10.1056/NEJMoa0902533

M3 - Journal article

SN - 0028-4793

VL - 362

SP - 416

EP - 426

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 5

ER -